21:36 , Jan 26, 2019 |  BioCentury  |  Product Development

Raising the BD bar

Innovator biotechs say that the business development bar has been raised for companies developing new modalities, with potential partners seeking proof of mechanism on top of proof of efficacy. A host of products based on...
17:59 , Apr 13, 2018 |  BC Week In Review  |  Clinical News

Valneva reports Phase I data for Lyme disease vaccine candidate

Valneva SE (Euronext Paris:VLA; VSE:VLA) reported interim data from a Phase I trial in 179 healthy volunteers ages 18-40 showing that Lyme disease candidate VLA15 (VLA15-101) met the primary endpoint by achieving a "favorable" safety...
23:53 , Feb 22, 2018 |  BC Innovations  |  Product R&D

Shooting for the universe

CureVac AG is bringing a new modality to the race for a universal flu vaccine with an mRNA program backed by a grant from the Bill & Melinda Gates Foundation. While the company believes its...
19:03 , Dec 8, 2017 |  BC Week In Review  |  Clinical News

Sanofi discontinues C. difficile vaccine

Sanofi (Euronext:SAN; NYSE:SNY) discontinued development of its late-stage Clostridium difficile vaccine (ACAM-CDIFF) after an interim analysis by the trial's IDMC concluded that the candidate is unlikely to meet the primary endpoint of the Phase III...
22:53 , May 26, 2017 |  BioCentury  |  Finance

Europe’s bellwether challenge

A healthy biotech ecosystem comprises a continuum from big pharma and bellwether biotechs at the top to private newcos at the bottom, with a mixture of liquidity events -- predominantly M&A -- to reward investors....
22:37 , Apr 19, 2017 |  BC Extra  |  Company News

Management tracks

Cardiovascular company MyoKardia Inc. (NASDAQ:MYOK) appointed David Meeker to its board. He is stepping down at the end of June as EVP and general manager of the Genzyme unit of Sanofi (Euronext:SAN; NYSE:SNY). Immunotherapy company...
16:00 , Mar 10, 2017 |  BC Extra  |  Company News

Management tracks

Orphan disease company Dynacure S.A.S. (Illkirch-Graffenstaden, France) named Stephane van Rooijen CEO and Frederic Legros COO. van Rooijen was CEO at Confo Therapeutics N.V. (Brussels, Belgium). Legros was VP and corporate head of business development...
20:31 , Dec 16, 2016 |  BC Week In Review  |  Financial News

Valneva completes private placement

Valneva raised €7.5 million ($7.9 million) through the sale of 2.9 million shares at €2.60 in a private placement with MVM Life Science Partners. Valneva SE (Euronext:VLA; VSE:VLA), Lyon, France ...
22:11 , Dec 13, 2016 |  BC Week In Review  |  Clinical News

VLA15-101: Ph I started

Valneva began a single-blind, dose-escalation, international Phase I trial to evaluate VLA15-101 in about 180 healthy volunteers. Valneva SE (Euronext:VLA; VSE:VLA), Lyon, France  Product: VLA15-101  Business: Infectious  Molecular target: Borrelia outer surface protein A (ospA)...
07:00 , Sep 1, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Lipoteichoic acid (LTA); heparin-binding EGF-like growth factor (HBEGF; DTR)

Infectious disease INDICATION: Clostridium Mouse studies suggest LTA glycan-based vaccines could help prevent Clostridium difficile infection (CDI). In a mouse challenge model of CDI, a compound composed of glycans from C. difficile LTA conjugated to...